BACKGROUND AND OBJECTIVE With constant incentives for healthcare payers to contain their pharmaceutical budgets, modelling policy decision impact became critical. The objective of this project was to test the impact of various policy decisions on pharmaceutical budget (developed for the European Commission for the project 'European Union (EU) Pharmaceutical expenditure forecast' - http://ec.eur...

The aim of this paper is to develop a methodology that is useful for analysing from a microeconomic perspective the incentives to entry, permanence and exit in the market for pharmaceutical generics under fuzzy conditions. In an empirical application of our proposed methodology, the potential towards permanence of labs with different characteristics has been estimated. The case we deal with is ...

Access to the French drug market is being impacted by an ongoing dramatic shift in practice as well as by two laws that came into force in December 2011. This new environment has been described and analyzed in two separate articles. This second article analyzes how this new environment will actually impact the access to French drug market. French drug market access will be increasingly driven b...

For many years European governments have sought to ensure a high degree of competition in off-patent pharmaceutical markets in order to generate price competition and consequently benefits such as improved patient access or savings for payers after patent expiry. The pharmaceutical industry believes that access to valuable new treatments and post-exclusivity competition are essential for the su...

Parenteral drug delivery is the second largest segment of the pharmaceutical market and accounts for nearly 30% of the market share. Currently, around 3.5 billion prefilled syringes are produced each year and that number is growing between 9%-10% annually. The Future of Alliances and Partnerships in the Prefilled Syringes Market to 2020 forecasts that the global market for prefilled syringes wi...

In 1997 and 1998 the Mexican government encouraged the introduction of generic drugs into Mexico, Latin America’s biggest and fastest-growing pharmaceutical market. In contrast to the situation in Brazil, where anti-retrovirals and HIV/AIDS treatment have been the centerpiece of a powerful stateled generics “revolution,” in Mexico the move to cheaper, copied medicines has made its strongest mar...

Broadly speaking, pharmaceutical policy in Spain has been unable to control either the price or the volume of drugs prescribed. Limited attempts have been made to bring together the regulation of the pharmaceutical market and policies, in pursuit of the desired goals of efficiency and quality. This paper assesses the regulation of the Spanish pharmaceutical market over the last two decades by e...

In today’s intensely competitive business environment, pharmaceutical companies are augmenting their product pipelines by both developing drugs on their own and inlicensing proprietary compounds or drug discovery–related technologies from smaller biotechnology companies. In this work, the OptFolio model of pharmaceutical R&D portfolio management is extended to evaluate partnership opportunities...

computable general equilibrium models are known as a powerful instrument in economic analyses and widely have been used in order to evaluate trade liberalization effects. the purpose of this study was to provide the impacts of trade openness on pharmaceutical industry using cge model.using a computable general equilibrium model in this study, the effects of decrease in tariffs as a symbol of tr...